MX2021015510A - Pirazolo[4,3-b]piridinas sustituidas y su uso como moduladores del receptor glun2b. - Google Patents

Pirazolo[4,3-b]piridinas sustituidas y su uso como moduladores del receptor glun2b.

Info

Publication number
MX2021015510A
MX2021015510A MX2021015510A MX2021015510A MX2021015510A MX 2021015510 A MX2021015510 A MX 2021015510A MX 2021015510 A MX2021015510 A MX 2021015510A MX 2021015510 A MX2021015510 A MX 2021015510A MX 2021015510 A MX2021015510 A MX 2021015510A
Authority
MX
Mexico
Prior art keywords
pyridines
glun2b receptor
substituted pyrazolo
receptor modulators
glun2b
Prior art date
Application number
MX2021015510A
Other languages
English (en)
Inventor
Christine Gelin
Afton Hiscox
Michael A Letavic
Brice Stenne
Andrew Samant
Jessica Wall
Curt Dvorak
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2021015510A publication Critical patent/MX2021015510A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pirazolo[4,3-b]piridinas sustituidas como ligandos del receptor GluN2B; tales compuestos pueden usarse en la modulación del receptor GluN2B y en composiciones farmacéuticas y métodos para el tratamiento de estados de enfermedad, trastornos, y afecciones mediadas por la actividad del receptor GluN2B.
MX2021015510A 2019-06-14 2020-06-12 Pirazolo[4,3-b]piridinas sustituidas y su uso como moduladores del receptor glun2b. MX2021015510A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962861674P 2019-06-14 2019-06-14
PCT/EP2020/066391 WO2020249791A1 (en) 2019-06-14 2020-06-12 SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Publications (1)

Publication Number Publication Date
MX2021015510A true MX2021015510A (es) 2022-04-11

Family

ID=71120146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015510A MX2021015510A (es) 2019-06-14 2020-06-12 Pirazolo[4,3-b]piridinas sustituidas y su uso como moduladores del receptor glun2b.

Country Status (10)

Country Link
US (2) US20220324860A1 (es)
EP (1) EP3983073A1 (es)
JP (1) JP2022536174A (es)
KR (1) KR20220020917A (es)
CN (1) CN113993583A (es)
AU (1) AU2020293642A1 (es)
BR (1) BR112021025136A2 (es)
CA (1) CA3143102A1 (es)
MX (1) MX2021015510A (es)
WO (1) WO2020249791A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
JP2022536773A (ja) 2019-06-14 2022-08-18 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロピラジン及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
EP3982958A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
MX2021015508A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de piridina y su uso como moduladores del receptor glun2b.
US20220324860A1 (en) 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
CR20210580A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b
AU2020290772A1 (en) 2019-06-14 2022-01-06 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407447D0 (en) 1994-04-14 1994-06-08 Glaxo Group Ltd Chemical compounds
DE69730980T2 (de) 1996-07-31 2006-02-23 Nikken Chemicals Co., Ltd. 6-phenyltetrahydro-1,3-oxazin-2-on derivate und medizinische zusammensetzungen, die sie enthalten
US6610723B2 (en) 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
CN100368411C (zh) 2002-03-28 2008-02-13 卫材R&D管理有限公司 作为c-Jun N-末端激酶抑制剂用于治疗神经变性疾病的7-氮杂吲哚类化合物
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
TW200604183A (en) 2004-02-18 2006-02-01 Astrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
RU2007110731A (ru) 2004-09-23 2008-10-27 Редди Юс Терапевтикс Новые соединения пиримидина, способ их получения и содержащие их композиции
WO2007115231A2 (en) 2006-03-30 2007-10-11 Chemocentryx, Inc. Cxcr4 modulators
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
EP2167464B1 (en) 2007-05-25 2014-12-03 AbbVie Deutschland GmbH & Co KG Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
CA2697663A1 (en) 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited Substituted pyrazole derivative
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
WO2009118187A1 (en) 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
WO2009157196A1 (ja) 2008-06-25 2009-12-30 武田薬品工業株式会社 アミド化合物
EP2308877B1 (en) 2008-08-05 2014-01-22 Daiichi Sankyo Company, Limited Imidazopyridin-2-one derivatives
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
JP5656848B2 (ja) 2008-10-16 2015-01-21 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体
EP2379561B1 (en) 2008-11-25 2015-11-04 University Of Rochester Mlk inhibitors and methods of use
WO2010108187A2 (en) 2009-03-20 2010-09-23 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
EP2579717A4 (en) 2010-06-09 2013-12-11 Merck Sharp & Dohme POSITIVE ALLOSTERIC MODULATORS OF MGLUR2
JP2012188363A (ja) 2011-03-09 2012-10-04 Dainippon Sumitomo Pharma Co Ltd アザベンゾイミダゾロン誘導体
WO2013060029A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp Allosteric modulators of metabotropic glutamate receptors
US9434743B2 (en) 2012-03-02 2016-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
WO2014124651A1 (en) 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
CA2901334A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Pyridine cdk9 kinase inhibitors
PE20151997A1 (es) 2013-03-15 2016-01-13 Plexxikon Inc Compuestos heterociclicos y usos de los mismos
CN109939113B (zh) 2013-06-21 2022-02-15 恒翼生物医药科技(上海)有限公司 双环溴结构域抑制剂
HUE042111T2 (hu) 2013-07-31 2019-06-28 Merck Patent Gmbh Piridinek, pirimidinek és pirazinok mint BTK inhibitorok, továbbá ezek alkalmazása
EP3180315B1 (en) 2014-08-15 2020-03-18 Janssen Pharmaceuticals, Inc. Pyrazoles
DK3180329T3 (da) 2014-08-15 2020-04-06 Janssen Pharmaceuticals Inc Triazoler som nr2b receptorinhibitorer
WO2016081649A1 (en) 2014-11-18 2016-05-26 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto
MA41803A (fr) 2015-03-24 2018-01-30 Almirall Sa Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques
ES2781867T3 (es) * 2015-07-09 2020-09-08 Janssen Pharmaceutica Nv 4-Azaindoles sustituidos y su utilización como moduladores del receptor GluN2B
WO2017139428A1 (en) 2016-02-10 2017-08-17 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as nr2b-selective nmda modulators
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
IL271149B2 (en) 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating S1P1 activity and methods of using them
US11008302B2 (en) 2018-04-04 2021-05-18 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators
CN110294756A (zh) 2019-06-04 2019-10-01 广州市原子高科同位素医药有限公司 GluN2B亚基靶向型中枢神经***正电子示踪剂及其制备
CR20210580A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b
US20220324860A1 (en) 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
AU2020290772A1 (en) 2019-06-14 2022-01-06 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
EP3982958A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
MX2021015508A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de piridina y su uso como moduladores del receptor glun2b.
JP2022536773A (ja) 2019-06-14 2022-08-18 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロピラジン及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用

Also Published As

Publication number Publication date
JP2022536174A (ja) 2022-08-12
US11161846B2 (en) 2021-11-02
CN113993583A (zh) 2022-01-28
AU2020293642A1 (en) 2022-01-20
WO2020249791A1 (en) 2020-12-17
CA3143102A1 (en) 2020-12-17
BR112021025136A2 (pt) 2022-01-25
KR20220020917A (ko) 2022-02-21
US20200392130A1 (en) 2020-12-17
EP3983073A1 (en) 2022-04-20
US20220324860A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
MX2021015510A (es) Pirazolo[4,3-b]piridinas sustituidas y su uso como moduladores del receptor glun2b.
PH12019500676A1 (en) Substituted 1h-imidazo[4,5-b]pyridin-2(3h)-ones and their use as glun2b receptor modulators
CR20210615A (es) Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
MX2021015506A (es) Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b.
WO2020106642A8 (en) 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
PH12017501140A1 (en) TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
WO2019193516A3 (en) Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
MY169268A (en) Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5-disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
GEP20207172B (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
MX2021015511A (es) Carbamatos de pirazina y sus usos como moduladores del receptor glun2b.
PH12019501324A1 (en) Pyrazolo[3,4-b]pyridines and imidazo [1,5-b] pyridazines as pde1 inhibitors
MX2020010879A (es) Carboxamidas biciclicas y metodos de uso de las mismas.
MX2022011310A (es) Azabiciclo y derivados de diazepina para tratar trastornos oculares.